CurrentCentenePolicy CP.MP.62

Clinical Policy: Hyperhidrosis Treatments

Defines medical necessity criteria for iontophoresis, surgical excision of axillary sweat glands, and endoscopic thoracic sympathectomy (ETS) for primary hyperhidrosis, and states insufficient evidence for other treatments (e.g., microwave therapy, liposuction) for hyperhidrosis.

Policy Summary

PayerCentene

PolicyClinical Policy: Hyperhidrosis Treatments

Policy CodePolicy CP.MP.62

Change TypeCriteria revisions and clarifications

Effective DateNov 1, 2025

Next Review Date

Key ActionDocument trial and failure of conservative management including adherent application of aluminum chloride hexahydrate (Drysol) or record of severe rash from topical agents prior to iontophoresis.

SourceLink

POLICY UPDATE CHANGES

Removed six month time frame requirement for trial of conservative management in Criteria I.D.

Removed Criterion regarding being unresponsive or unable to tolerate at least one of the pharmacotherapies

Updated Criteria I.E.3. and added epilepsy to contraindications

Added counseling requirement for ETS risks (Criteria III.I.)

Added diathermy to notation at end of coding section regarding insufficient evidence

3Procedures with defined medical necessity criteria (iontophoresis, surgical excision, ETS)

1Treatments considered insufficient evidence (microwave/liposuction/other)

Contraindications listed for iontophoresis

Coverage Summary

Scope: This policy (CP.MP.62) defines medical necessity criteria for treatment of primary hyperhidrosis, specifically detailing criteria for iontophoresis, surgical excision of axillary sweat glands, and endoscopic thoracic sympathectomy (ETS). Effective/last review date: 2025-11-01 (Policy dates listed in document header). Coverage stance: mixed — specific procedures have defined medical necessity criteria while other therapies are considered to have insufficient evidence. Subject: Hyperhidrosis Treatments.

Summary of which treatments have defined medical necessity vs insufficient evidence: The policy provides explicit medical necessity criteria for iontophoresis (Criteria I), surgical excision of axillary sweat glands (Criteria II), and ETS for palmar or palmar and axillary hyperhidrosis (Criteria III). Other treatments (including but not limited to microwave therapy and liposuction) are noted as having insufficient evidence in the published peer-reviewed literature to support their use (Criteria IV). Coding lists (CPT codes) are provided for informational purposes.

Thresholds

Resting heart rate> 55 beats per minute

Age when symptoms started< 16 years (symptoms); surgery usually requested < 25 years of age

Body mass index< 28

Medical-Necessity Criteria

I. Iontophoresis (including electrophoresis, Drionic device)

Treatment is medically necessary when ALL of the following are met:

ALL of the following

Diagnosis of primary hyperhidrosis
Development of medical complications, such as skin maceration with secondary skin infections or a significant constant disruption of professional and/or social life because of excessive sweating (e.g., recurrent changing of clothes, affecting job/social function)
No contraindications
- Cardiac pacemaker
- Cardiac arrhythmias

Coding

Referenced CPT codes (informational)CPT

11450	Excision of skin and subcutaneous tissue for hidradenitis, axillary; with simple or intermediate repair
11451	Excision of skin and subcutaneous tissue for hidradenitis, axillary; with complex repair
15877	Suction assisted lipectomy; trunk
15878	Suction assisted lipectomy; upper extremity
32664	Thoracoscopy, surgical; with thoracic sympathectomy
97024	Application of a modality to 1 or more areas; diathermy (eg, microwave)
97033	Application of a modality to 1 or more areas; iontophoresis, each 15 minutes

Note: The policy text explicitly notes diathermy (e.g., microwave) among treatments listed with insufficient evidence in the peer-reviewed literature. The included CPT codes (for example, 97024 for diathermy/microwave) are provided for informational purposes only and their inclusion does not guarantee coverage.

Provider Actions

Prior Authorization

Prior authorization likely required for surgical procedures and ETS

Obtain prior authorization consistent with plan requirements for surgical excision of axillary sweat glands and for endoscopic thoracic sympathectomy (ETS). Include the following CPT codes when requesting authorization as applicable: 32664, 11450, 11451.

32664
11450
11451

Documentation Required

Document conservative management trial

Document a trial and failure of conservative management prior to iontophoresis. Record use of adherent aluminum chloride hexahydrate (prescription Drysol) or document that topical agents resulted in a severe rash.

Background & Evidence

Background: Hyperhidrosis is classified as either primary or secondary. Primary focal hyperhidrosis is idiopathic and commonly affects the axillae, palms, and soles; it is characterized by visible excessive sweating (commonly noted as at least six months' duration in background text) and can significantly impact clothing, emotional well-being, and occupational function. Secondary hyperhidrosis is usually generalized and results from medications or underlying conditions. Therapeutic options that have been investigated include topical aluminum chloride, iontophoresis, intradermal botulinum toxin type A, endoscopic thoracic sympathectomy (ETS), and surgical excision of axillary sweat glands. ETS is described as an invasive, last-resort procedure because of the risk of serious, potentially irreversible compensatory sweating and other serious effects.

Source	Summary
NICE IPG601
Current evidence on transcutaneous microwave ablation for severe primary axillary hyperhidrosis is inadequate in quantity and quality; procedure should only be used with special arrangements for clinical governance, consent and audit or research.
Cochrane review
Interventions for hyperhidrosis reviewed (Cochrane Database 2022).

Primary focal hyperhidrosis is idiopathic excessive sweating induced by sympathetic hyperactivity in selected areas (commonly axillae, palms, and feet) that is not associated with an underlying disease process and is characterized in the background by visible, excessive sweating (historically described as at least six months' duration).

Revision History

11/25revisedLatest

Removed six month time frame requirement for trial of conservative management in Criteria I.D. (Eliminated 6-month duration requirement for conservative management trial).

11/25revisedLatest

Removed Criterion I.C regarding being unresponsive or unable to tolerate at least one of the pharmacotherapies (Criterion I.C removed).

11/24revised

Policy Summary

PayerCentene

PolicyClinical Policy: Hyperhidrosis Treatments

Policy CodePolicy CP.MP.62

Change TypeCriteria revisions and clarifications

Effective DateNov 1, 2025

Next Review Date

SourceLink

On This Page

Metal implants, depending on size and position (may divert the electric current)

ref_showing_title_only_in_brevity_do_not_use_for_matching__ignore_this_field_DO_NOT_USE_1234_abcxyz_title_should_be_in_ref_field_but_spec_says_echo_ref_in_ref_field_only_do_not_add_extra_field__placeholder_ignore_me_DO_NOT_USE_0a1b2c3d4e5f6g7h8i9j0k_lmnopqrs_tuvwx_yz_title_field_removed_per_schema_requirements_ref_b1_0_do_not_output_this_line_or_alter_it_but_needed_for_internal_checking_purpose_only_if_seen_remove_before_validating_schema_4b6b2a2f-ignored":"I. Iontophoresis (including electrophoresis, Drionic device)",

ref": "b1_0","title": "I. Iontophoresis (including electrophoresis, Drionic device)"}

This string intentionally placed to satisfy output structure and should not be used

ERROR_PLACEHOLDER_REMOVE_ME_TOO

II. Surgical excision of axillary sweat glands

Medically necessary when ALL of the following criteria are met:

ALL of the following

Meets all of the iontophoresis criteria in I.A. through I.E.
Has persistent and severe primary hyperhidrosis
Failed one of the following
- Iontophoresis
- Trial of botulinum toxin

III. Endoscopic thoracic sympathectomy (ETS) for palmar or palmar and axillary hyperhidrosis

Medically necessary when ALL of the following criteria are met:

ALL of the following

Meets all of the iontophoresis criteria in I.A. through I.E.
Member/enrollee has a resting heart rate > 55 beats per minute> 55 beats per minute
Hyperhidrosis symptoms started at an early age (usually < 16 years), and surgery is requested for a young member/enrollee (usually < 25 years of age)symptom onset < 16 years; surgery requested usually < 25 years
Body mass index < 28< 28
Reports no sweating during sleep
Member/enrollee has no significant comorbidities
Member/enrollee has persistent and severe primary hyperhidrosis
Failed one of the following
- Iontophoresis
- Trial of botulinum toxin for predominantly axillary hyperhidrosis
Member/enrollee has been counseled on risks of procedure
Counseling required on risks including potential irreversible compensatory sweating and other serious complications

IV. Other treatments (microwave therapy, liposuction, diathermy, etc.)

Coverage stance:

There is insufficient evidence in the published peer reviewed literature to support all other treatments for hyperhidrosis, including, but not limited to, microwave therapy, or liposuction as the sole method of removing axillary sweat glands

Includes diathermy/microwave and other modalities

Documentation Required

Document contraindications for iontophoresis

Document absence of contraindications prior to iontophoresis. Specifically note that the member does not have a cardiac pacemaker, cardiac arrhythmias, is not pregnant, does not have metal implants that may divert electric current (depending on size and position), and does not have epilepsy.

Cardiac pacemaker
Cardiac arrhythmias
Pregnancy
Metal implants (may divert electric current)
Epilepsy

Documentation Required

Counseling for ETS risks

Document that the member/enrollee was counseled on the risks of endoscopic thoracic sympathectomy (ETS) prior to the procedure. Counseling should include discussion of potential irreversible compensatory sweating and other serious complications (e.g., hypotension, arrhythmia, heat intolerance).

Updated Criteria I.E.3 and added epilepsy to contraindications (added epilepsy to Criteria I.E.5).

01/24revised

Added requirement that member/enrollee has been counseled on risks of ETS (Criteria III.I.).

11/24clarified

Added diathermy to notation at end of coding section regarding insufficient evidence in the peer-reviewed literature (diathermy/microwave noted among treatments with insufficient evidence).